The new Bruton's tyrosine kinase inhibitors SPA8007 and SPA8009 reduce stemness and invasiveness of patient-derived glioblastoma tumorspheres.

ABSTRACT: Glioblastoma (GBM), the most prevalent primary brain tumor, remains incurable due to the presence of cancer stem cells (CSCs), which can be isolated as tumorspheres (TSs) that exhibit classical characteristics of CSCs, including stemness and invasiveness. The significantly elevated expression of Bruton's tyrosine kinase (BTK) in GBM tissues identifies BTK as a potential therapeutic target in GBM. Consequently, ibrutinib, an FDA-approved BTK inhibitor for hematological malignancies, has been repurposed as a candidate for GBM treatment, demonstrating inhibitory effects on the proliferation, stemness, and invasiveness of GBM cell lines and TSs. However, its broad-spectrum activity targeting other Tec family kinases and members of the epidermal growth factor receptor family, poses potential li

SUBMITTER: Jo E 

PROVIDER: S-EPMC12595426 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature